preview

Chronic Myeloid Leukaemia (CML)

Satisfactory Essays
Open Document

Chronic myeloid leukaemia (CML) is one of the most dangerous bone marrow diseases with an initial chronic stage lasting for 3-5 years. It changes to a very fast phase called accelerated phase and then to the blast phase in which it leads later to death1. Besides (CML) is a type of cancer that affects the blood cells by raising the level of the immature white blood cells (leukocytes) in the bone marrow and which leads later to circulate in the blood stream. These crowded immature blood cells do not perform their vital role in defending the body against infectious organisms properly, and that leads to leukaemia disease progression.2, 3 On the other hand leukaemia is classified into four kinds: acute lymphocytic leukaemia (ALL), acute …show more content…

They reported that the deletion of a part of chromosome and then addition to another chromosome leads to creation of Philadelphia chromosome then later leads the leukaemia pathogenesis symptoms to appear.10
1973: Janet Rowley analysed that the Philadelphia chromosome (ph) of myeloid leukaemia is formed by a deletion of a long arm from chromosome 22 and then addition of this arm to the end of chromosome 9. In addition Janet found that the amount of additional material to chromosome 9 (9q+) is equal to the amount of the lost material from chromosome 22 (22q-) 11
1980s: researchers found that chronic myeloid leukaemia is achieved by translocation of a BCR gene of chromosome 22 to an ABL gene of chromosome 9 then the two genes make diffusion to form an 8-kilobase RNA that is responsible for tyrosine proteins synthesis which is the starting stage of chronic myelogenous leukaemia.12
1990s: the researchers start to synthesize a number of tyrosine kinase inhibitors especially the tyrosine that is coded by ABL/BCR that plays a vital role in development of chronic myeloid leukaemia. Moreover imatinib which is 2-phenylaminopyrimidine molecule is one of the most important structure that inhibit the activity of proteins that’s coded by ABL and BCR genes. …show more content…

14 CML attacks 1 to 2 cases per 100,000 people per year which is about 15% of adult, and the patients are between 45 and 55 years and about 85% of the patients are in chronic phase. On the other hand the symptoms that appear in chronic myelogenous leukaemia patients are fatigue, weight loss, abdominal fullness, bleeding, purpura, splenomegaly, leukocytosis, anaemia, and thrombocytosis.

Get Access